The mechanism(s) underlying ibrutinib-induced hypertension is unknown but is likely related to endothelial dysfunction, where the inhibition of BTK has been shown to interfere with nitric oxide synthesis [31], leading to increased vascular resistance and hypertension. The gene discussed is BTK; the disease is endothelial dysfunction.